Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics

Journal of Psychiatric Research

Volumn 41, Issue 8, 2007, Pages 652-658

  Medina Hernandez V ^a   Ramos Loyo, J ^b   Luquin, S ^b   Sánchez, L F Cerdán ^a   Garcia Estrada J ^a   Navarro Ruiz, A ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Instituto de Neurociencias   (Mexico)

Author keywords

Lipid peroxidation; Neuron specific enolase; Neuronal damage; Oxidative stress; Refractory schizophrenics

Indexed keywords

4 HYDROXYNONENAL; MALONALDEHYDE; NEURON SPECIFIC ENOLASE;

ADULT; ARTICLE; BLOOD LEVEL; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DISEASE SEVERITY; EMOTIONAL DISORDER; HUMAN; LIPID PEROXIDATION; MALE; NERVE CELL LESION; NERVE DEGENERATION; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SCORING SYSTEM; SPECTROPHOTOMETRY; WITHDRAWAL SYNDROME;

EID: 34047111880     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2006.02.010     Document Type: Article

References (45)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Ünal S., Sögüt S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002) 995-1005
2. American Psychiatric Association. DSMIV. Diagnostic and statistical manual of mental disorders, 4th ed. Washington (DC), 1995.
3. Bartlett E., Brodie J., Simkowits P., Schlösser R., Dewey S., and Lindenmayer J. Effect of haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. American Journal of Psychiatry 155 (1998) 337-343
4. Brenner H.D., and Merlo M.C. Definition of therapy resistant schizophrenia and its assessment. European Psychiatry 10 (1995) 11-18
5. Burbaeva G.S., and Zaiko S.D. Concentration of neuron and non-neuron-specific enolase isoenzymes in different structures of the brains of mentally healthy subjects and schizophrenic patients. Zh Nevropatol Psikhiatr Im S S Korsakova 1 (1987) 104-109
6. Buttke T., and Sandstrom P. Oxidative stress as a mediator of apoptosis. Immunology Today 15 (1994) 7-10
7. Egan M.F., El-Mallakh R.S., Suddath R.L., Lohr J.B., Bracha H.S., and Wyatt R.J. Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia. Psychiatry Research 43 (1992) 187-195
8. Fenton W.S., Hibbeln J., and Michael K. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 47 (2000) 8-21
9. Harding C., Zubin J., and Strauss S. Chronicity in schizophrenia revisited. British Journal of Psychiatry 161 (1992) 13-17
10. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., and Fenton W.S. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biological Psychiatry 53 (2003) 431-441
11. Joober R., Rouleau G., Lal S., Dixon M., O'Driscoll G., Palmour R., et al. Neuropsychological impairments in neuroleptic-responder vs. nonresponder schizophrenic patients and healthy volunteers. Schizophrenia Research 53 (2002) 229-238
12. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic: a-double blind comparison with chlorpromazine. Archive General of Psychiatry 45 (1988) 789-796
13. Kay S., Opler L., and Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia (1992), Multi-Health systems Inc., Manual Toronto
14. Keefe R., Mohns R., and Silverman J. Characteristics of kraepelinian schizophrenia and their relation to premorbid social functioning. In: Angrist B.O., and Schulz C.H. (Eds). The neuroleptic nonresponsive patients: characterization and treatment (1990), American Psychiatric Press, Washington (DC)
15. Keller J.N., Hanni K.B., and Markesbery W.R. 4-Hydroxynonenal increases neuronal susceptibility to oxidative stress. Journal of Neuroscience Research 58 (2000) 823-830
16. Kramer K., Voss H.-P., Grimberger J.A., Timmerman H., and Basr A. The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and b-adrenoreceptor density: is the damage in erythrocytes a reflection of brain damage caused by complete cerebral ischemia and by hypoxia?. Biochemical and Biophysical Research 149 (1987) 568-575
17. Lieberman J., Duncan G., and Sheitman B. An integrated view of pathophysiological models of schizophrenia. Brain Research Review 29 (1999) 250-256
18. Mahadik S., and Mukherjee S. Free-radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research 19 (1996) 1-17
19. Mahadik S., Mukherjee S., Scheffer R., Corrente E., and Mahadik J. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biological Psychiatry 43 (1998) 674-679
20. Marangos P. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annals Review Neuroscience 10 (1987) 269-295
21. McCreadie R.G., MacDonald E., Wiles D., Campbell G., and Paterson J.R. The nithsdale schizophrenia surveys, XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive diskinesia, and in normal subjects. British Journal of Psychiatry 167 (1995) 610-617
22. Missler U., Wiesmann M., Friedrich C., and Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 28 (1997) 1956-1960
23. Morrow J., Frei B., Longmire A., Gaziano J., Lynch S., Shyr Y., et al. Increased in circulating products of lipid peroxidation (f2-isoprotanes) in smokers: smoking as a cause of oxidative damage. New England Journal of Medicine 332 (1995) 1198-1203
24. Overrall J.E. Brief psychiatric rating scale. Psychological Reports 10 (1962) 799
25. Pall H.S., Williams A.C., Blake D.R., and Lunec J. Evidence of enhanced lipid peroxidation in cerebrospinal fluid of patients taking phenothiazine. Lancet 2 (1987) 596-599
26. Parikh V., Khan M.M., and Mahadik S. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research 37 (2003) 43-51
27. Parma A.M., Marangos P.J., and Goodwin F.K. A more sensitive radioimmunoassay for neuron-specific enolase suitable for cerebrospinal fluid determinations. Journal of Neurochemistry 36 (1981) 1093-1096
28. Peet M., Laughrane J., Rangarajan N., and Reynold G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. International Journal of Clinical Psychopharmacology 8 (1993) 151-153
29. Peet M., Laughrane J., Mellor J., and Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins, Leukotrienes Essential Fatty Acids 55 (1996) 71-75
30. Peet M., Zhi J.Z., Selvam K., and Ramchand C. Plasma TBARS levels in unmedicated chronic schizophrenic patients. Schizophrenia Research 24 (1997) 1-2
31. Puri B.K., Richardson A.J., Horrobin D.F., Easton T., Saced N., Oatridge A., et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalization of blood fatty acids, reduced neuronal membrane phospholipids turnover and structural brain changes. International Journal of Clinical Practice 54 (2000) 57-63
32. Ramos J., Cerdán L., Guevara M., and Amezcua C. Impairments in attention and facial emotion recognition in treatment refractory and non-refractory schizophrenics evaluated through an odd-ball paradigm. Revista de Neurologia 33 (2001) 1027-1032
33. Ramos J., Cerdán L., Guevara M., Amezcua C., and Sanz A. Abnormal EEG patterns in treatment-resistant schizophrenic patients. International Journal of Neuroscience 109 (2001) 47-59
34. Ramos-Loyo J., Cerdán L.F., and Guevara M.A. Evaluation of olanzapine effects on attention and emotional recognition processes through event related potentials in treatment refractory schizophrenics. In: Columbus F. (Ed). Focus on nonverbal communication research (2006), Nova Science Publishers, Inc.
35. Reddy R.D., and Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes Essential Fatty Acids 55 (1996) 33-43
36. Reddy R., Keshavan M., and Yao J.K. Reduced plasma antioxidants in first episode patients with schizophrenia. Schizophrenia Research 62 (2003) 205-212
37. Simonian N.A., and Coyle J.T. Oxidative stress in neurodegenerative diseases. Pharmacology and Toxicology 36 (1996) 82-106
38. Stadtmnan E., and Levin R. Protein oxidation. Annals of New York Academy of Sciences 899 (2000) 191-208
39. Stahl W. Lipid oxidation and antioxidants. Current Opinion Clinic Nutrition & Metabolic Care 3 (2000) 121-126
40. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathology International 49 (1999) 91-102
41. Vermuyten K., Lowenthal A., and Karcher D. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorder by means of a sensitive enzyme immunoassay. Clinical Chemical Acta 187 (1990) 69-78
42. Yao J.K., Reddy R.D., and Van Kammen D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Research 80 (1998) 29-39
43. Yao J.K., Reddy R.D., and Van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biological Psychiatry 45 (1999) 1512-1515
44. Yao J.K., Reddy R.D., and Van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Research 97 (2000) 137-151
45. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research (2006) 291-300